ESR1 and breast carcinoma: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are well-known biomarkers for predicting the subtype, prognosis, and treatment options for breast cancer patients [68–71, 78].